All news

Delphi advisor in connection with rights issue and listing of Fluicell AB (Publ) on Nasdaq First North

Delphi has acted as legal advisor to Fluicell AB (publ) in connection to a rights issue of 32,7 MSEK and listing on Nasdaq First North. The first day of trade is April 18.

Fluicell is based in Gothenburg Sweden and the company has commercialized a product portfolio to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. As a further development of Fluicell’s existing product portfolio, the company is developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar™ Retina. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled. More information about the company is found on

The Delphi team mainly consisted of Andreas Wirén (Partner), Daniel Jessen Winbo (Senior Associate) and Anders Hulegårdh (Partner).